Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun:68:103401.
doi: 10.1016/j.ebiom.2021.103401. Epub 2021 May 26.

SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors

Matthew Frieman  1 , Anthony D Harris  2 , Ramin Sedaghat Herati  3 , Florian Krammer  4 , Alberto Mantovani  5 , Maria Rescigno  6 , Mohammad M Sajadi  7 , Viviana Simon  8
Affiliations

SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors

Matthew Frieman et al. EBioMedicine. 2021 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Matthew Frieman, Anthony D. Harris, Ramin Sedaghat Herati, and Mohammad M. Sajadi have nothing to disclose. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 95 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor (US Provisional Application No 62/994,252). Viviana Simon is also listed on the serological assay patent application as co-inventor (US Provisional Application No 62/994,252). Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. Alberto Mantovani has consulted for Pfizer and Astra Zeneca. Maria Rescigno serves as a consultant for DiaSorin and Gelesis. Diasorin supports Humanitas for the development of diagnostic assays related to COVID-19 and has filed patent applications with Alberto Mantovani as co-inventor.

References

    1. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021 - PMC - PubMed
    1. Saadat S, Tehrani ZR, Logue J, Newman M, Frieman MB, Harris AD. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021 - PMC - PubMed
    1. Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6) - PMC - PubMed
    1. Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, John C., Prostko JC. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nature Medicine. 2021;384 - PMC - PubMed
    1. Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, et al. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in recovered individuals with symptomatic COVID-19. J Clin Invest. 2021 May 6:149154. doi: 10.1172/JCI149154. Online ahead of print.PMID: 33956667 - DOI - PMC - PubMed

MeSH terms